Trastuzumab emtansine, [7][8] sold under the brand name Kadcyla, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin) covalently linked to the cytotoxic agent DM1. [9][10][11][12] Trastuzumab alone stops growth of cancer cells by binding to the HER2 receptor, whereas trastuzumab emtansine undergoe...

Ado-trastuzumab emtansine is approved to treat: Breast cancer that is HER2 positive and has already been treated with a taxane and trastuzumab. It is used: as adjuvant therapy in patients with early-stage breast cancer. It is used in these patients when invasive breast cancer is found in the tissue removed during surgery.

作用机理：ado-trastuzumabemtansine是一种新型抗体药物，由曲妥珠单抗和小分子微管抑制剂DM1偶联而成，产生协同抗癌作用。 在原发性乳腺癌患者中观察到有25%-30%的患者HER2过度表达，曲妥珠单抗是一种 重组DNA 衍生的人源化单克隆抗体，选择性地作用于HER-2的胞外部位。 DM1是一种美坦辛（某些文献译为美登素，maytansine）衍生物，发现与20世纪70年代初期，通过与长春花位点结合，抑制 微管蛋白 聚集，这是美坦辛首次批准用于临床。 黑框警告：肝毒 …

2024年11月15日 · Ado- trastuzumab emtansine is used to treat a HER2-positive breast cancer. ado-trastuzumab emtansine is used both for early breast cancer and for breast cancer that has spread to other parts of the body (metastatic). Ado-trastuzumab emtansine is usually given after other treatments have failed.

2025年1月15日 · The primary analysis of KATHERINE, a phase 3, open-label trial, showed that the risk of invasive breast cancer or death was 50% lower with adjuvant trastuzumab emtansine (T-DM1) than with...

2012年11月8日 · Trastuzumab emtansine (T-DM1) is an antibody–drug conjugate that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent...

Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate that is effective and generally well tolerated when administered as a single agent to treat advanced breast cancer. Efficacy has now been demonstrated in randomized trials as first line, second line, and later than the second line treatment of advanced breast cancer.

Current evidence indicates that ADCs are both effective and tolerable in elderly patients, demonstrating improved progression-free survival (PFS) and overall survival (OS) alongside a manageable safety profile.

2020年1月21日 · Ado-trastuzumab emtansine (T-DM1) is an antibody–drug conjugate (ADC) that has been added to the armamentarium for the treatment of HER2+ BC.

2018年12月5日 · Trastuzumab emtansine (T-DM1), an antibody–drug conjugate of trastuzumab and the cytotoxic agent emtansine (DM1), a maytansine derivative and microtubule inhibitor, provides benefit in...